Stocks · Health care · Biological Products, (No Diagnostic Substances)

EXELIXIS, INC.

EXEL Clue Score84
United States Fiscal year ends January CIK 0000939767 Results filed 29 Oct 2026

What the insiders did No buying or selling

By person

17 insiders · 0 transactions
Insider
Role
Bought
Sold
Net
Holding
Worth
Change
Michael Morrissey
President and CEO
—
—
—
3,366,335
$180.64M
+41.9%
David Edward Johnson
Director
—
—
—
1,553,262
$83.35M
+1.8%
Stelios Papadopoulos
Director
—
—
—
1,197,595
$64.26M
−6.4%
Christopher J. Senner
EVP and CFO
—
—
—
952,317
$51.10M
+32.0%
Jeffrey Hessekiel
EVP & General Counsel
—
—
—
693,396
$37.21M
+30.6%
Dana Aftab
EVP, Research and Development
—
—
—
594,741
$31.91M
+18.9%
Amy C. Peterson
EVP Prod Dev & Med Aff & CMO
—
—
—
465,393
$24.97M
+44.5%
Patrick J. Haley
EVP, Commercial
—
—
—
357,638
$19.19M
−6.0%
Jack L Wyszomierski
Director
—
—
—
284,384
$15.26M
−18.6%
George Poste
Director
—
—
—
127,199
$6.83M
−24.7%
Maria C Freire
Director
—
—
—
109,186
$5.86M
+20.0%
Brenda Hefti
SVP and General Counsel
—
—
—
106,762
$5.73M
+17.8%
Tomas J. Heyman
Director
—
—
—
50,649
$2.72M
+36.8%
Bob Oliver
Director
—
—
—
29,487
$1.58M
−20.3%
Julie Smith
Director
—
—
—
28,957
$1.55M
+168.7%
Mary C Beckerle
Director
—
—
—
16,079
$862.80K
−53.1%
Sue Gail Eckhardt
Director
—
—
—
16,079
$862.80K
−53.1%

No percentages here. These insiders hold more than one class of share between them, and the share count on file covers one of them rather than all. Dividing the two would compare different things.